The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: eliminating the use of brute force.
作者信息
Ratain Mark J, Tannock Ian F, Lichter Allen S
机构信息
Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL; and.
Optimal Cancer Care Alliance, and.
出版信息
Blood Adv. 2022 Sep 13;6(17):5041-5044. doi: 10.1182/bloodadvances.2022007793.
Abstract
摘要
相似文献
1
The dosing of ibrutinib and related Bruton's tyrosine kinase inhibitors: eliminating the use of brute force.依鲁替尼及相关布鲁顿酪氨酸激酶抑制剂的给药：摒弃盲目用药
Blood Adv. 2022 Sep 13;6(17):5041-5044. doi: 10.1182/bloodadvances.2022007793.
2
Ibrutinib, a Bruton's tyrosine kinase inhibitor, a new risk factor for cryptococcosis.伊布替尼，一种布鲁顿酪氨酸激酶抑制剂，一种新型隐球菌病的危险因素。
Med Mal Infect. 2020 Nov;50(8):742-745. doi: 10.1016/j.medmal.2020.07.005. Epub 2020 Aug 7.
3
Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.布鲁顿酪氨酸激酶抑制剂可抑制慢性淋巴细胞白血病中 FcγRIIA 介导的血小板对细菌的反应。
Front Immunol. 2021 Nov 29;12:766272. doi: 10.3389/fimmu.2021.766272. eCollection 2021.
4
Noncatalytic Bruton's tyrosine kinase activates PLCγ variants mediating ibrutinib resistance in human chronic lymphocytic leukemia cells.非催化性布鲁顿酪氨酸激酶激活 PLCγ 变异体，介导伊布替尼耐药的人慢性淋巴细胞白血病细胞。
J Biol Chem. 2020 Apr 24;295(17):5717-5736. doi: 10.1074/jbc.RA119.011946. Epub 2020 Mar 17.
5
Treatment of Chronic Lymphocytic Leukemia After Discontinuation of Bruton's Tyrosine Kinase Inhibitors.布鲁顿酪氨酸激酶抑制剂停药后慢性淋巴细胞白血病的治疗。
Hematol Oncol Clin North Am. 2021 Aug;35(4):793-806. doi: 10.1016/j.hoc.2021.03.008. Epub 2021 May 27.
6
Bruton's tyrosine kinase Inhibitors and Cardiotoxicity: More Than Just Atrial Fibrillation.布鲁顿酪氨酸激酶抑制剂与心脏毒性：不止是房颤。
Curr Oncol Rep. 2021 Aug 3;23(10):113. doi: 10.1007/s11912-021-01102-1.
7
Dermatological Toxicities of Bruton's Tyrosine Kinase Inhibitors.布鲁顿酪氨酸激酶抑制剂的皮肤毒性。
Am J Clin Dermatol. 2020 Dec;21(6):799-812. doi: 10.1007/s40257-020-00535-x.
8
Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.ROR1 失稳增强伊布替尼对体内慢性淋巴细胞白血病的活性。
Pharmacol Res. 2020 Jan;151:104512. doi: 10.1016/j.phrs.2019.104512. Epub 2019 Nov 12.
9
Bruton's tyrosine kinase inhibitors and the kidney: Focus on ibrutinib.布鲁顿酪氨酸激酶抑制剂与肾脏：聚焦于伊布替尼
J Oncol Pharm Pract. 2020 Oct;26(7):1735-1737. doi: 10.1177/1078155220904406. Epub 2020 Feb 13.
10
Effect of Bruton's tyrosine kinase inhibitors on platelet aggregation in patients with acute myocardial infarction.布鲁顿酪氨酸激酶抑制剂对急性心肌梗死患者血小板聚集的影响。
Thromb Res. 2019 Jul;179:64-68. doi: 10.1016/j.thromres.2019.04.024. Epub 2019 Apr 24.
引用本文的文献
1
Improving the Dosing Schedules of Targeted Anticancer Agents.改善靶向抗癌药物的给药方案。
Pharmaceuticals (Basel). 2025 Jun 6;18(6):848. doi: 10.3390/ph18060848.
2
Updates on the Management of Autoimmune Bullous Diseases.自身免疫性大疱性疾病的治疗进展
Indian Dermatol Online J. 2024 Aug 30;15(5):758-769. doi: 10.4103/idoj.idoj_740_23. eCollection 2024 Sep-Oct.
本文引用的文献
1
Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia.利扎鲁单抗，一种口服 BTK 抑制剂，治疗免疫性血小板减少症。
N Engl J Med. 2022 Apr 14;386(15):1421-1431. doi: 10.1056/NEJMoa2110297.
2
Review of the development of BTK inhibitors in overcoming the clinical limitations of ibrutinib.BTK 抑制剂克服伊布替尼临床限制的发展综述。
Eur J Med Chem. 2022 Feb 5;229:114009. doi: 10.1016/j.ejmech.2021.114009. Epub 2021 Nov 22.
3
Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.布鲁顿酪氨酸激酶（BTK）抑制剂与自身免疫性疾病：解析 BTK 抑制剂的特异性特征及近期临床试验的成败。
Front Immunol. 2021 Nov 3;12:662223. doi: 10.3389/fimmu.2021.662223. eCollection 2021.
4
Fenebrutinib in H antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial.芬尼布特治疗 H 抗组胺药抵抗性慢性自发性荨麻疹：一项随机 2 期试验。
Nat Med. 2021 Nov;27(11):1961-1969. doi: 10.1038/s41591-021-01537-w. Epub 2021 Nov 8.
5
Distinct Effects of Ibrutinib and Acalabrutinib on Mouse Atrial and Sinoatrial Node Electrophysiology and Arrhythmogenesis.伊布替尼和阿卡替尼对小鼠心房和窦房结电生理及心律失常发生的不同影响。
J Am Heart Assoc. 2021 Nov 16;10(22):e022369. doi: 10.1161/JAHA.121.022369. Epub 2021 Nov 2.
6
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma.伊布替尼联合维奈托克治疗复发或难治性套细胞淋巴瘤的剂量探索研究。
Blood Adv. 2022 Mar 8;6(5):1490-1498. doi: 10.1182/bloodadvances.2021005357.
7
The Drug-Dosing Conundrum in Oncology - When Less Is More.肿瘤学中的给药难题——少即是多。
N Engl J Med. 2021 Oct 14;385(16):1445-1447. doi: 10.1056/NEJMp2109826. Epub 2021 Oct 9.
8
Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?索托拉西布的剂量优化：美国食品药品监督管理局是在传达什么信息吗？
J Clin Oncol. 2021 Nov 1;39(31):3423-3426. doi: 10.1200/JCO.21.01371. Epub 2021 Sep 20.
9
Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies.在患有 B 细胞恶性肿瘤的患者中，阿卡替尼及其活性代谢物 ACP-5862 的暴露-反应分析。
Br J Clin Pharmacol. 2022 May;88(5):2284-2296. doi: 10.1111/bcp.15087. Epub 2021 Oct 17.
10
Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial.口服脑穿透 BTK 抑制剂替洛鲁替尼治疗复发性多发性硬化症的安全性和疗效：一项 2b 期、随机、双盲、安慰剂对照试验。
Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4.
Zotero 插件